Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $78
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. XENE | 0.00 |
Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:
XENE) with a Buy and lowers the price target from $80 to $78.